35 results
424B5
IMNM
Immunome, Inc.
14 May 24
Prospectus supplement for primary offering
8:48am
are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors
8-K
EX-10.1
k4207q2x96v6q y1mz0
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
j2h3h4 37fv
14 Feb 24
Other Events
4:11pm
424B5
i1szy8murh5 4jwzm5
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
z149zh3q
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.2
9n04d42o9mzd83450u
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
wrs86dl
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
jc3u2i1u075o21vmjln
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
424B3
hinf2vz 45vs
28 Aug 23
Prospectus supplement
9:10am
S-4/A
2l8gwmksemwp9vtx5
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
parhga
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm